Key result
Transcatheter tricuspid valve therapies have emerged as safe and effective alternatives to surgery for high-risk patients with severe tricuspid regurgitation, showing promising short- and mid-term results.
Why the study?
Surgical correction of tricuspid regurgitation carries poor outcomes, driving interest in transcatheter approaches for patients at high or prohibitive surgical risk.
Transcatheter tricuspid valve interventions represent a promising, safe, and effective alternative to surgery for high-risk patients with severe tricuspid regurgitation.
Tricuspid valve regurgitation is an insidious pathology that is associated with increased mortality if left untreated. Conversely, surgical correction of tricuspid regurgitation is burdened by poor outcomes, especially when right ventricular dysfunction, kidney disease, or liver disease occur. There is, therefore, increasing interest in transcatheter approaches as an alternative to surgery in patients at high or prohibitive surgical risk. The development of percutaneous devices to treat tricuspid regurgitation has several technical challenges, mainly because of the complexity of valve anatomy, thus requiring accurate patient selection. Here we review the currently available transcatheter approaches to treat severe tricuspid regurgitation.
No takes yet. Share an insight, caveat, or question.
Ascione et al. (2020) conducted a review in Severe tricuspid regurgitation. Transcatheter tricuspid valve therapies vs. Surgery or medical therapy was evaluated. Transcatheter tricuspid valve therapies have emerged as safe and effective alternatives to surgery for high-risk patients with severe tricuspid regurgitation, showing promising short- and mid-term results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: